RCUS
Arcus Biosciences, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | +1 | 62.00M | $1.91B | +8 | −7 |
| Q1 2026 | 85 | -2 | 57.45M | $1.24B | +6 | −8 |
| Q4 2025 | 87 | -1 | 64.26M | $1.53B | +1 | −2 |
| Q3 2025 | 20 | +2 | 36.84M | $500.99M | +2 | — |
| Q2 2025 | 15 | -1 | 35.18M | $286.34M | — | −1 |
| Q1 2025 | 13 | +2 | 11.54M | $90.60M | +4 | −2 |
| Q4 2024 | 11 | 0 | 8.18M | $121.86M | +1 | −1 |
| Q3 2024 | 10 | 0 | 4.70M | $71.80M | — | — |
| Q2 2024 | 10 | — | 4.00M | $60.94M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 1.83M | — | $27.93M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.23M | — | $18.78M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.23M | — | $18.78M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 467.16K | — | $7.11M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 467.16K | — | $7.11M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 175.71K | — | $2.68M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 105.13K | — | $1.60M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 82.40K | — | $1.25M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 36.50K | — | $556,000 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 30.77K | — | $468,551 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 24.52K | — | $373,501 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 11.97K | — | $182,364 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 119.00M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.83K sh · $84,810
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗